Bristol-Myers Squibb

Chicago, Illinois

OncologyFiled/ApprovedListed · BMY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

3d agoTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Filed/Approved

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
PHASE1/PHASE2 registered
Mar 26, 2026
Advanced Renal Cell Carcinoma (RCC) · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
ClinicalTrials.gov · NCT07293351 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Feb 3, 2026
Relapsed/Refractory Small Cell Lung Cancer · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
ClinicalTrials.gov · NCT07325136 (opens the source filing in a new tab)
Trial
Study registered
Jan 16, 2026
Schizophrenia · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users
ClinicalTrials.gov · NCT07571148 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jan 15, 2026
Renal Cell Carcinoma · RECRUITING · sponsor: Bristol-Myers Squibb · A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
ClinicalTrials.gov · NCT07195682 (opens the source filing in a new tab)
Trial
PHASE1 registered
Mar 25, 2025
Advanced Malignant Tumors · RECRUITING · sponsor: Bristol-Myers Squibb · A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
ClinicalTrials.gov · NCT06764771 (opens the source filing in a new tab)
Trial
PHASE1 registered
Mar 24, 2025
Advanced Solid Tumors With Homozygous MTAP Deletion · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
ClinicalTrials.gov · NCT06672523 (opens the source filing in a new tab)
Trial
PHASE3 registered
Feb 25, 2025
Extensive-Stage Small Cell Lung Cancer · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
ClinicalTrials.gov · NCT06646276 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Feb 4, 2025
Lung Cancer, Breast Cancer · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
ClinicalTrials.gov · NCT06618287 (opens the source filing in a new tab)
Trial
PHASE1 registered
Oct 10, 2024
Advanced Solid Tumors · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
ClinicalTrials.gov · NCT06544655 (opens the source filing in a new tab)
Trial
PHASE1 registered
Sep 6, 2024
High-grade Serous Ovarian Carcinoma (HGSOC), Uterine Serous Carcinoma (USC), Non-small Cell Lung Cancer (NSCLC) · RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
ClinicalTrials.gov · NCT06476808 (opens the source filing in a new tab)
Trial
PHASE1 registered
May 29, 2024
Acute Myeloid Leukemia, Myelodysplastic Syndrome · RECRUITING · sponsor: Bristol-Myers Squibb · Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
ClinicalTrials.gov · NCT06419634 (opens the source filing in a new tab)
Trial
PHASE2 registered
Nov 27, 2023
NSCLC · TERMINATED · sponsor: Bristol-Myers Squibb · A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov · NCT06094296 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Nov 9, 2023
Advanced Solid Tumors · TERMINATED · sponsor: Bristol-Myers Squibb · A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
ClinicalTrials.gov · NCT06024174 (opens the source filing in a new tab)
Trial
PHASE2 registered
Nov 6, 2023
Melanoma · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
ClinicalTrials.gov · NCT06101134 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Jun 6, 2023
Advanced Solid Tumors · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
ClinicalTrials.gov · NCT05888831 (opens the source filing in a new tab)
Trial
PHASE3 registered
Mar 6, 2023
Melanoma · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
ClinicalTrials.gov · NCT05625399 (opens the source filing in a new tab)
Trial
PHASE1 registered
Dec 9, 2022
Advanced Solid Tumors · COMPLETED · sponsor: Bristol-Myers Squibb · A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
ClinicalTrials.gov · NCT05625412 (opens the source filing in a new tab)
Trial
Study registered
Nov 23, 2022
Muscle-invasive Urothelial Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma
ClinicalTrials.gov · NCT05779592 (opens the source filing in a new tab)
Trial
PHASE2 registered
Nov 14, 2022
Carcinoma, Non-Small-Cell Lung · TERMINATED · sponsor: Bristol-Myers Squibb · A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
ClinicalTrials.gov · NCT05577715 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Sep 13, 2022
Lymphoma, Non-Hodgkin, Hodgkin Disease · TERMINATED · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
ClinicalTrials.gov · NCT05255601 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Nov 30, 2021
Advanced Solid Tumors · COMPLETED · sponsor: Bristol-Myers Squibb · A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
ClinicalTrials.gov · NCT05134948 (opens the source filing in a new tab)
Trial
PHASE1 registered
Aug 9, 2021
Advanced Solid Tumors · COMPLETED · sponsor: Bristol-Myers Squibb · A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
ClinicalTrials.gov · NCT04943900 (opens the source filing in a new tab)
Trial
PHASE2 registered
Jul 12, 2021
Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
ClinicalTrials.gov · NCT04857034 (opens the source filing in a new tab)
Trial
PHASE3 registered
May 21, 2021
Clear Cell Renal Cell Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
ClinicalTrials.gov · NCT04810078 (opens the source filing in a new tab)
Trial
PHASE4 registered
Dec 17, 2020
Kidney Neoplasms · COMPLETED · sponsor: Bristol-Myers Squibb · A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
ClinicalTrials.gov · NCT04513522 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jan 15, 2020
Urinary Bladder Neoplasms · TERMINATED · sponsor: Bristol-Myers Squibb · A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
ClinicalTrials.gov · NCT04149574 (opens the source filing in a new tab)
Trial
PHASE3 registered
Nov 5, 2019
Carcinoma, Non-Small-Cell Lung · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
ClinicalTrials.gov · NCT04025879 (opens the source filing in a new tab)
Trial
Study registered
Sep 19, 2019
Advanced or Metastatic Renal Cell Carcinoma · COMPLETED · sponsor: Bristol-Myers Squibb · A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan
ClinicalTrials.gov · NCT04043975 (opens the source filing in a new tab)
Trial
PHASE3 registered
Jun 21, 2019
Renal Cell Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
ClinicalTrials.gov · NCT03873402 (opens the source filing in a new tab)
Trial
PHASE1 registered
Mar 26, 2019
Advanced Solid Cancers · COMPLETED · sponsor: Bristol-Myers Squibb · An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
ClinicalTrials.gov · NCT03956680 (opens the source filing in a new tab)
Trial
PHASE3 registered
Nov 6, 2018
Urinary Bladder Neoplasms, Muscle-Invasive Bladder Cancer · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
ClinicalTrials.gov · NCT03661320 (opens the source filing in a new tab)
Trial
PHASE3 registered
Apr 18, 2018
Hepatocellular Carcinoma, Liver Cancer · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
ClinicalTrials.gov · NCT03383458 (opens the source filing in a new tab)
Trial
Study registered
Jan 21, 2018
Renal Cell Carcinoma, Renal Cell Cancer, Adenocarcinoma Of Kidney, Adenocarcinoma, Renal Cell, Kidney Cancer, Cancer of the Kidney · COMPLETED · sponsor: Bristol-Myers Squibb · Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer
ClinicalTrials.gov · NCT03455452 (opens the source filing in a new tab)
Trial
PHASE1 registered
Jan 4, 2017
Cancer · COMPLETED · sponsor: Bristol-Myers Squibb · Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
ClinicalTrials.gov · NCT02966548 (opens the source filing in a new tab)
Trial
PHASE3 registered
Mar 22, 2016
Various Advanced Cancer · ACTIVE_NOT_RECRUITING · sponsor: Bristol-Myers Squibb · An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
ClinicalTrials.gov · NCT02632409 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 76%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.97name similarity 100% · semantic similarity 81% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.97name similarity 100% · shared principal investigator / founder · same city
Shared principal investigator or founder links the trial record at 0.97name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.97name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.96name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.96name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.96name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.96name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.95name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.94name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.94name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.94name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.94name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.94name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.94name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.94name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.93name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.91name similarity 100% · shared principal investigator / founder
Shared principal investigator or founder links the trial record at 0.78name similarity 100% · shared principal investigator / founder · same city · same therapeutic area
Shared principal investigator or founder links the trial record at 0.75name similarity 100% · shared principal investigator / founder · same city
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.73name similarity 100% · shared principal investigator / founder · same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
3d agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
3d agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
2w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
2w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
2w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
2w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
2w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
2w agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
3w agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
3w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
3w agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer
4w agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer
4w agoTrial completedSource (opens the source filing in a new tab)
Phase I trial registered: A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
5w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
5w agoTrial recruitingSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
6w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
6w agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
6w agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma
7w agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users
2mo agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
3mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
3mo agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
3mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
3mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase II trial registered: A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
3mo agoTrial registeredSource (opens the source filing in a new tab)
Phase I trial registered: Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
3mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
3mo agoTrial recruitingSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
6mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
7mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
7mo agoTrial completedSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
8mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
9mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
9mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
9mo agoTrial registeredSource (opens the source filing in a new tab)
Phase III trial registered: A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
10mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
10mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
10mo agoTrial registeredSource (opens the source filing in a new tab)
Phase II trial registered: A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors
12mo agoTrial registeredSource (opens the source filing in a new tab)
Filed/Approved trial registered: A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
Jul 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
Jul 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Jun 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors
Jun 2025Trial completedSource (opens the source filing in a new tab)
Phase II trial registered: A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Jun 2025Trial registeredSource (opens the source filing in a new tab)
Phase II trial registered: A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Phase I trial registered: A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Apr 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
Feb 2025Trial completedSource (opens the source filing in a new tab)
Phase I trial registered: Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
Feb 2025Trial completedSource (opens the source filing in a new tab)
Study registered, no phase assigned: A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan
Feb 2025Trial registeredSource (opens the source filing in a new tab)
Trial completed: A Study of Nivolumab Plus Ipilimumab in Participants With Renal Cell Cancer in the Real World Setting in Japan
Feb 2025Trial completedSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

PHASE1/PHASE2 registered

PHASE1/PHASE2 registered

Study registered

PHASE1 registered

PHASE1 registered

PHASE1 registered

PHASE3 registered

PHASE1/PHASE2 registered

PHASE1 registered

PHASE1 registered

PHASE1 registered

PHASE2 registered

PHASE1/PHASE2 registered

PHASE2 registered

PHASE1/PHASE2 registered

PHASE3 registered

PHASE1 registered

Study registered

PHASE2 registered

PHASE1/PHASE2 registered

PHASE1/PHASE2 registered

PHASE1 registered

PHASE2 registered

PHASE3 registered

PHASE4 registered

PHASE3 registered

PHASE3 registered

Study registered

PHASE3 registered

PHASE1 registered

PHASE3 registered

PHASE3 registered

Study registered

PHASE1 registered

PHASE3 registered